TATVASpecialty Chemicals
Tatva Chintan Pharma Chem Limited — Profit & Loss Statement
₹1052.40
-5.07%
Tatva Chintan Pharma Chem Limited Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -1.13 Cr | -73656.00 | — |
| Tax Rate For Calcs | 0.25 | 0.30 | 0.30 | 0.08 | — |
| Normalized EBITDA | 36.53 Cr | 75.70 Cr | 66.10 Cr | 116.75 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -3.77 Cr | -0.09 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -3.77 Cr | -0.09 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 5.71 Cr | 30.35 Cr | 45.49 Cr | 95.87 Cr | — |
| Reconciled Depreciation | 27.66 Cr | 25.61 Cr | 9.55 Cr | 8.18 Cr | — |
| Reconciled Cost Of Revenue | 198.94 Cr | 174.18 Cr | 234.59 Cr | 207.68 Cr | — |
| EBITDA | 36.53 Cr | 75.70 Cr | 62.33 Cr | 116.65 Cr | — |
| EBIT | 8.87 Cr | 50.10 Cr | 52.78 Cr | 108.47 Cr | — |
| Net Interest Income | -1.29 Cr | -6.53 Cr | -3.27 Cr | -0.56 Cr | — |
| Interest Expense | 1.29 Cr | 6.53 Cr | 8.00 Cr | 4.35 Cr | — |
| Normalized Income | 5.71 Cr | 30.35 Cr | 48.12 Cr | 95.96 Cr | — |
| Net Income From Continuing And Discontinued Operation | 5.71 Cr | 30.35 Cr | 45.49 Cr | 95.87 Cr | — |
| Total Expenses | 376.16 Cr | 350.91 Cr | 362.16 Cr | 330.49 Cr | — |
| Diluted Average Shares | 2.34 Cr | 2.29 Cr | 2.22 Cr | 2.15 Cr | — |
| Basic Average Shares | 2.34 Cr | 2.29 Cr | 2.22 Cr | 2.15 Cr | — |
| Diluted EPS | 2.44 | 13.26 | 20.52 | 44.59 | — |
| Basic EPS | 2.44 | 13.26 | 20.52 | 44.59 | — |
| Diluted NI Availto Com Stockholders | 5.71 Cr | 30.35 Cr | 45.49 Cr | 95.87 Cr | — |
| Net Income Common Stockholders | 5.71 Cr | 30.35 Cr | 45.49 Cr | 95.87 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 5.71 Cr | 30.35 Cr | 45.49 Cr | 95.87 Cr | — |
| Minority Interests | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Including Noncontrolling Interests | 5.71 Cr | 30.35 Cr | 45.49 Cr | 95.87 Cr | — |
| Net Income Continuous Operations | 5.71 Cr | 30.35 Cr | 45.49 Cr | 95.87 Cr | — |
| Tax Provision | 1.87 Cr | 13.21 Cr | -0.71 Cr | 8.25 Cr | — |
| Pretax Income | 7.58 Cr | 43.57 Cr | 44.78 Cr | 104.12 Cr | — |
| Other Non Operating Income Expenses | 2.31 Cr | 7.51 Cr | 0.37 Cr | 0.13 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -3.77 Cr | -0.09 Cr | — |
| Net Non Operating Interest Income Expense | -1.29 Cr | -6.53 Cr | -3.27 Cr | -0.56 Cr | — |
| Interest Expense Non Operating | 1.29 Cr | 6.53 Cr | 8.00 Cr | 4.35 Cr | — |
| Operating Income | 6.55 Cr | 42.59 Cr | 58.73 Cr | 100.81 Cr | — |
| Operating Expense | 177.22 Cr | 176.73 Cr | 127.56 Cr | 122.81 Cr | — |
| Other Operating Expenses | 96.64 Cr | 96.36 Cr | 42.13 Cr | 44.61 Cr | — |
| Depreciation And Amortization In Income Statement | 27.66 Cr | 25.61 Cr | 9.55 Cr | 8.18 Cr | — |
| Depreciation Income Statement | 27.66 Cr | 25.61 Cr | 9.40 Cr | 8.13 Cr | — |
| Gross Profit | 183.77 Cr | 219.32 Cr | 186.30 Cr | 223.62 Cr | — |
| Cost Of Revenue | 198.94 Cr | 174.18 Cr | 234.59 Cr | 207.68 Cr | — |
| Total Revenue | 382.71 Cr | 393.50 Cr | 420.89 Cr | 431.29 Cr | — |
| Operating Revenue | 382.71 Cr | 393.50 Cr | 420.89 Cr | 431.29 Cr | — |
| Amortization | — | 0.21 Cr | 0.15 Cr | 0.05 Cr | 0.06 Cr |
| Interest Income | — | 3.28 Cr | 5.33 Cr | 4.67 Cr | 0.36 Cr |
| Rent Expense Supplemental | — | 1.54 Cr | 1.88 Cr | 1.14 Cr | 1.45 Cr |
| Other Special Charges | — | 0.15 Cr | 3.59 Cr | 0.05 Cr | 0.03 Cr |
| Write Off | — | 0.14 Cr | 0.18 Cr | 0.04 Cr | 0.02 Cr |
| Total Other Finance Cost | — | 0.58 Cr | 0.60 Cr | 0.88 Cr | 0.46 Cr |
| Interest Income Non Operating | — | 3.28 Cr | 5.33 Cr | 4.67 Cr | 0.36 Cr |
| Selling General And Administration | — | 28.40 Cr | 33.83 Cr | 37.44 Cr | 21.45 Cr |
| Selling And Marketing Expense | — | 22.51 Cr | 28.77 Cr | 33.06 Cr | 18.78 Cr |
| General And Administrative Expense | — | 5.89 Cr | 5.07 Cr | 4.38 Cr | 2.67 Cr |
| Rent And Landing Fees | — | 1.54 Cr | 1.88 Cr | 1.14 Cr | 1.45 Cr |
| Research And Development | — | — | — | — | 0.28 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Tatva Chintan Pharma Chem Limited
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.